VYNE
Income statement / Annual
Last year (2024), VYNE Therapeutics Inc.'s total revenue was $501,000.00,
an increase of 18.16% from the previous year.
In 2024, VYNE Therapeutics Inc.'s net income was -$39.83 M.
See VYNE Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$501,000.00 |
$424,000.00 |
$477,000.00 |
$14.76 M |
$20.99 M |
$443,000.00 |
$10.64 M |
$4.58 M |
$674,000.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$3.35 M
|
$1.39 M
|
$350,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$501,000.00
|
$424,000.00
|
$477,000.00
|
$11.41 M
|
$19.60 M
|
$93,000.00
|
$10.64 M
|
$4.58 M
|
$674,000.00
|
$0.00
|
| Gross Profit Ratio |
1
|
1
|
1
|
0.77
|
0.93
|
0.21
|
1
|
1
|
1
|
0
|
| Research and Development Expenses |
$30.95 M
|
$16.31 M
|
$18.39 M
|
$24.96 M
|
$43.53 M
|
$53.76 M
|
$52.99 M
|
$29.01 M
|
$11.26 M
|
$2.92 M
|
| General & Administrative Expenses |
$13.19 M
|
$13.38 M
|
$16.39 M
|
$0.00
|
$0.00
|
$22.48 M
|
$12.19 M
|
$5.17 M
|
$3.75 M
|
$1.69 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.19 M
|
$13.38 M
|
$16.39 M
|
$54.48 M
|
$89.54 M
|
$22.48 M
|
$12.19 M
|
$5.17 M
|
$3.75 M
|
$1.69 M
|
| Other Expenses |
$0.00
|
$0.00
|
$363,000.00
|
-$135,000.00
|
$1.11 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$44.14 M
|
$29.68 M
|
$34.77 M
|
$79.44 M
|
$133.08 M
|
$76.24 M
|
$65.18 M
|
$34.18 M
|
$15.01 M
|
$4.61 M
|
| Cost And Expenses |
$44.14 M
|
$29.68 M
|
$34.77 M
|
$82.79 M
|
$134.47 M
|
$76.24 M
|
$65.18 M
|
$34.18 M
|
$15.01 M
|
$4.61 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.09 M
|
$517,000.00
|
$264,000.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$5.61 M
|
$4.39 M
|
$2.54 M
|
$3.09 M
|
$517,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$4,000.00
|
$0.00
|
$72,000.00
|
$109,000.00
|
$341,000.00
|
$350,000.00
|
$22,000.00
|
$8,000.00
|
$4,000.00
|
$0.00
|
| EBITDA |
-$43.63 M |
-$29.26 M |
-$34.22 M |
-$38.94 M |
-$251.10 M |
-$94.08 M |
-$54.54 M |
-$29.59 M |
-$14.33 M |
-$4.61 M |
| EBITDA Ratio |
-87.09
|
-69
|
-71.14
|
-4.62
|
-5.34
|
-172.1
|
-5.13
|
-6.46
|
-21.26
|
0
|
| Operating Income Ratio |
-87.1
|
-69
|
-71.9
|
-4.61
|
-5.41
|
-172.1
|
-5.13
|
-6.46
|
-21.26
|
0
|
| Total Other Income/Expenses Net |
$3.83 M
|
$1.39 M
|
$363,000.00
|
-$5.75 M
|
-$142.35 M
|
-$19.11 M
|
$3.09 M
|
$517,000.00
|
$264,000.00
|
$0.00
|
| Income Before Tax |
-$39.80 M
|
-$27.87 M
|
-$33.93 M
|
-$73.78 M
|
-$255.83 M
|
-$73.70 M
|
-$51.45 M
|
-$29.08 M
|
-$14.07 M
|
-$4.61 M
|
| Income Before Tax Ratio |
-79.45
|
-65.74
|
-71.14
|
-5
|
-12.19
|
-166.37
|
-4.84
|
-6.35
|
-20.87
|
0
|
| Income Tax Expense |
$4,000.00
|
$0.00
|
$13,000.00
|
-$448,000.00
|
-$258,000.00
|
-$3.24 M
|
$3.09 M
|
-$8,000.00
|
$0.00
|
$0.00
|
| Net Income |
-$39.83 M
|
-$28.45 M
|
-$33.95 M
|
-$73.33 M
|
-$255.57 M
|
-$70.46 M
|
-$51.45 M
|
-$29.08 M
|
-$14.07 M
|
-$4.61 M
|
| Net Income Ratio |
-79.51
|
-67.1
|
-71.16
|
-4.97
|
-12.17
|
-159.06
|
-4.84
|
-6.35
|
-20.87
|
0
|
| EPS |
-0.94 |
-2.77 |
-10.65 |
-25.65 |
-141.9 |
-149.48 |
-170.94 |
-101.65 |
-87.78 |
-28.75 |
| EPS Diluted |
-0.94 |
-2.77 |
-10.65 |
-25.65 |
-141.9 |
-149.48 |
-170.94 |
-101.65 |
-87.78 |
-28.75 |
| Weighted Average Shares Out |
$42.59 M
|
$10.27 M
|
$3.19 M
|
$2.86 M
|
$1.80 M
|
$471,388.00
|
$300,954.00
|
$286,037.00
|
$160,266.00
|
$160,266.00
|
| Weighted Average Shares Out Diluted |
$42.59 M
|
$10.27 M
|
$3.19 M
|
$2.86 M
|
$1.80 M
|
$471,388.00
|
$300,954.00
|
$286,037.00
|
$160,266.00
|
$160,266.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
